Skip to main content
OpenTrials
Completed

NCT Number: NCT00207077

Study of Cetuximab in Combination With Tarceva in Patients With Solid Tumors

The purpose of this study is to find a safe and effective dose of the combination of cetuximab (Erbitux) and Tarceva (erlotinib).

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Neoplasms

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Primary location

Christiana Care Health Services, Inc.

Newark, Delaware, 19718, United States

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Measurable disease
  • Life expectancy of at least 3 months
  • Must have at least one prior chemotherapy containing a platinum

Exclusion criteria

  • Known or documented brain metastases
  • Prior cetuximab therapy

Treatment and study plan

Cetuximab + Erlotinib

Drug

IV solution + tablet, IV+ oral, ERB 100 mg/m2, 200 mg/m2, 250 mg/m2 IV + Erl 150 mg tablet, ERB weekly/ Erl once daily, Until disease progression.

Other names: Erbitux

Primary outcomes

  1. Safety and efficacy of the combination of Tarceva and Erbitux

Secondary outcomes

  1. Radiographic response

Sponsors and collaborators

Lead sponsor

Eli Lilly and Company

Industry

Registry information

Official study title

A Phase I Study of Cetuximab in Combination With Erlotinib in Patients With Advanced Solid Malignancies

Important dates

Study start
2005
Primary completion
2007
Study completion
2007
First posted
Sep 21, 2005
Registry last updated
Oct 28, 2015

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.